Topic

Outperform Rating

A collection of 2 issues

Wedbush Rates Rocket Pharmaceuticals Outperform with $32 Target

Wedbush initiates coverage on Rocket Pharmaceuticals (RCKT) with an Outperform rating and a $32 price target, signaling strong growth potential.

Wedbush Rates Rocket Pharmaceuticals 'Outperform' with $32 Target

Wedbush Securities has initiated coverage on Rocket Pharmaceuticals (RCKT) with an Outperform rating and a $32 price target, forecasting significant growth by 2025. Explore what makes Rocket a promising investment.